MEDBOT-B (02252) surged more than 7% in early trading. As of writing, the stock was up 5.7%, trading at HK$26.7 with a turnover of HK$115 million. The company recently announced the successful completion of the world's first in-vivo animal experiment for "large model autonomous surgery," powered by its self-developed "MicroGenius" multi-modal autonomous surgical large model. This achievement is unprecedented in existing public literature and medical practice, marking the first time globally that a multi-modal autonomous surgical large model has driven a surgical robot to complete critical procedural steps autonomously in a live animal scenario. Notably, the company previously announced that, based on internal preliminary statistics, the cumulative orders for its core products in laparoscopy, orthopedics, and vascular intervention have exceeded 230 units. Among them, the core product Toumai laparoscopic surgical robot (Toumai) has accumulated over 160 commercialized orders globally, including nearly 120 new orders secured this year. According to public statistics, Toumai's global order volume for 2025 has already ranked second worldwide.